Global Cancer Anorexia-Cachexia Syndrome Drug Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|全球癌症食慾不振·惡病質症候群(CACS)治療藥市場(2020年∼2027年) Global Cancer Anorexia-Cachexia Syndrome Drug Market - 2020-2027|
|出版日期: 2021年05月12日||內容資訊: 英文 180 Pages||
由於癌症患者人數的增加、惡病質發病率的增加以及各大製藥公司努力開發治療有效的新藥，在預測期內全球癌症厭食和惡病質將出現增長。預計將推動綜合徵 (CACS) 治療市場的增長。
The Global Cancer Anorexia-Cachexia Syndrome Drug Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Cancer anorexia-cachexia syndrome (CACS) is a multifactorial syndrome defined as a progressive wasting disorder. Loss of both skeletal muscle and fat distinguishes it from starvation. It incorporates a complex metabolic syndrome with abnormal carbohydrate, protein and lipid metabolism. Some progress has been made in understanding multifactorial pathophysiology. Although incompletely understood, the cancer syndrome is likely to arise from imbalanced interactions between inflammatory cytokines, neuropeptides, hormones and tumor-derived products.
The increasing burden of cancer cases worldwide also increases the prevalence of cancer cachexia among cancer patients, which is characterized by systemic inflammation, harmful protein and energy balance, and an involuntary loss of lean body mass. Because of this factor, most of the major players are focused on R&D activities to develop highly effective novel drugs in the treatment of cancer cachexia are expected to drive the market.
Increasing prevalence of Cancer Cases, coupled with increased incidence of cachexia is expected to drive the global Cancer Anorexia-Cachexia Syndrome Drug market during the forecast period.
As per the World Health Organisation (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Additionally, according to the data published by the society on CACS in 2018 it was estimated that 0.5-1% of total population were suffering from cancer-induced cachexia. This number has led to an increase in the adoption of cancer cachexia drugs.
The presence of potential drugs in the clinical pipeline is expected to drive the global Cancer Anorexia-Cachexia Syndrome Drug market during the forecast period.
At present, the treatment options for cachexia among cancer patients are very limited to drugs like progestogens, corticosteroids, NSAIDS and others. These drugs proved their efficacy, but at present, no drug being specifically approved for this condition to treat. Thus, the demand for significant market players is increasing to fulfil through R&D and novel drugs in the market. For instance, to study the safety of APD209 in patients with advanced malignancy and active cachexia by Acacia Pharma Ltd is currently under phase 2 clinical trials.
High cost associated with treatment, is likely to hinder the market growth.
Apart from the increasing prevalence of cancer anorexia cachexia globally, certain other factors are limiting the growth of the market were high cost of treatment as well as limited reimbursement policies and also stringent government regulations. For instance, As per the data published in PubMed.gov and National Library of Medicine NIH, the cost of inpatient was significantly higher in cachexia than non-cachexic lung cancer patients, $13,560 and $13 190. In general, the cost of cachexic and non-cachexic cancer patients is about 14 751 and 13 928 has been the major factors hampering the market growth.
COVID-19 Impact Analysis
Due to the covid-19 pandemic outbreak, the market for Global Cancer Anorexia-Cachexia Syndrome Drug Market was seen to be raised slightly, As per the research article published in the British Journal of Nutrition, 2020, changes in the nutritional status and weight loss during hospitalization are primarily reported in some populations, but it is not entirely in COVID-19 patients. But the symptoms and associated conditions of COVID-19 lead to nutritional status deterioration, leading to cachexia and also, cancer patients are at a higher risk of being infected with COVID-19, as they are immunocompromised and their ability to fight against the infection is very low compared to others, leading to the higher chances of developing multiple organ-related complications or cachexia.
Based on Product Type, the global Cancer Anorexia-Cachexia Syndrome Drug market is segmented into Progestogens, Corticosteroids, Combination therapies, Others
The progestogens segment dominates the market due to a comparatively low cost of progestogens and high bioavailability and high efficacy in the cancer anorexia cachexia treatment. Many placebo-controlled, double-blind clinical trials have demonstrated that progestational agents, such as megestrol (Megace) and medroxyprogesterone, can lead to appetite stimulation and weight gain in patients with cancer-anorexia and cachexia. As per the data published in cancer network in the United States, an Oral formulation of megestrol is considerably less expensive that is $35 than the liquid form and also less side-effects than corticosteroids.
Corticosteroids are the first agents to undergo placebo-controlled, double-blind evaluation for possible use in cancer cachexia. The first such trial, conducted in the 1970s by Moertel and colleagues at the Mayo Clinic, demonstrated that corticosteroids could stimulate appetite in patients with advanced, incurable cancer. Dexamethasone (3 to 8 mg/d) is a reasonable option for clinical use. Known detriments to corticosteroid use include the well-known toxicities associated with long-term administration, including myopathy, peptic ulcer disease, infection, adrenal suppression, and hyperglycemia. However, many patients with advanced cancer anorexia and cachexia do not survive long enough to suffer from these toxicities.
Amino acid supplements, particularly glutamine, L-Carnitine and L arginine, and these amino acids are being evaluated in combination with metoclopramide, oxandrolone (Oxandrin) to assess their potential benefit.
Based on Distribution channel, the hospital pharmacy are expected to dominate the Global Cancer Anorexia-Cachexia Syndrome Drug market during the forecast period
The hospital pharmacies held the largest share in the global Cancer Anorexia-Cachexia Syndrome Drug market. This is mainly owing to increasing number of patients suffering from cancers and other conditions like cachexia which are treated in hospitals equipped with advanced infrastructure and adequate facilities and with potential drugs. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
North America region holds the largest market share of the global Cancer Anorexia-Cachexia Syndrome Drug
North America is expected to hold a large market share in the global Cancer Anorexia-Cachexia Syndrome Drug Market due to the growing incidence of cancer cases. The International Agency for Research on Cancer (IARC) claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel products, the total availability of advanced technological tools, FDA approval of new drugs and many companies are developing oncology products.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, in march 2019, Helsinn Healthcare S.A announced the drug Anamorelin undergoing Phase 3 trials to evaluate the effect in Cancer Anorexia Cachexia in Non-Small Cell Lung Cancer patients.
The Global Cancer Anorexia-Cachexia Syndrome Drug Market is moderately competitive with some key competitors like Pfizer Inc, Helsinn Healthcare, Acacia Pharma Ltd, PsiOxus Therapeutics Ltd, Incyte Corp, Aeterna Zentaris Inc, Obexia AG, Aphios Corporation, Merck & Co, Novartis AG. The growth of these companies is attributed to product launch, acquisition of independent companies and investments in multiple sectors. For instance, OHR/AVR118 studied by Ohr Pharmaceutical Inc is currently under Phase 2 trials for open label study in advanced cancer cachexia patients.
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
PF-06946860, sponsored by Pfizer Inc., is currently under Phase I clinical trials. The purpose of this trial is to determine the safety of PF-06946860 in the treatment of colorectal cancer, non-small-cell lung cancer, Pancreatic cancer, cachexia.
In July 2019- Pfizer Inc. entered into an agreement with Mylan in order to create a new global pharmaceutical company, Viatris to expand its global reach, strengthen its market position.
The Global Cancer Anorexia-Cachexia Syndrome Drug Market report would provide an access to an approx. market data 53 table, 44 figures and 300 pages.
LIST NOT EXHAUSTIVE